Breast Cancer Segment by Application to Account Larger Share in Microcarriers Market during 2022–2030

According to our latest study on "Microcarriers Market Forecast to 2030 – Global Analysis –Product, Equipment, Application, and End User," the market is expected to reach US$ 1,625.84 million in 2030 from US$ 4,178.86 million in 2022. The report highlights trends prevailing in the market, and factors driving and hindering the microcarriers market growth. 

The microcarriers market growth is due to the need for cell therapies with rising incidence of cancer and infectious diseases, and the increasing popularity of outsourcing cell and gene therapy manufacturing boosts the market growth. However, the high cost of biologics and cell-based therapies hampers the market growth.
 
The microcarriers market, by application, is segmented into biopharmaceutical production, cell and gene therapy, tissue engineering, regenerative medicine, and others. In 2022, the biopharmaceutical production segment held the largest market share, and same is estimated to register the fastest CAGR of 13.1% during 2022–2030. Biopharmaceutical production segment is further subsegmented into therapeutic production and vaccine production. Microcarriers are an established technology in the biopharmaceutical industry, which, in combination with stirred-tank bioreactors, can provide the necessary environment for large-scale production of adherent cells. Biodegradable materials used in the production of microcarriers have the capability to solve in vitro disease modeling. Microcarriers find applications in biopharmaceutical industries as they expand the spectrum of controllable biodegradation.

Asia Pacific is the fastest-growing region of the global newborn screening market in 2022. The growth of the market in this region can be associated with the growing emphasis of businesses on cost optimization, burgeoning efforts to streamline clinical processes, supportive government policies, and increasing number of clinical trials. The 13th Chinese plan expected a more than 4% contribution of the biotechnology industry to the GDP in 2020, which would be nearly 10–20 life-science parities. More than 100 life-science parks controlled by local governments are functional across China, and these centers entice enterprises with tax advantages and subsidies. State, provincial, and local governments are reported to have already invested more than US$ 100 billion in the biosciences sector to meet the goals of the five-year plan of China. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials across the world. The country currently has nearly 400 ongoing CAR-T trials centered on hematology, and oncology and solid tumors. In 2021, the National Medical Products Administration (NMPA) approved Fosun Kite's Yescarta and JW Therapeutics' Relma-cel, with which cell therapies in China entered a new era.
 
Teijin Ltd, Bio-Rad Laboratories Inc, denovoMATRIX GmbH, Sartorius AG, Danaher Corp, Corning Inc, Eppendorf SE, Percell Biolytica AB, Asahi Kasei Corp, Polysciences Inc  are among the leading companies operating in the vital signs monitoring devices market.    

Companies operating in the microcarriers market adopt various organic and inorganic strategies. Growth strategies mainly include product launches and product approvals, mergers & acquisitions, collaborations, and partnerships are among the growth strategies witnessed in the microcarriers market. 

A few of the significant developments by key market players are listed below.

• In October 2023, Kuraray Co., Ltd. developed PVA hydrogel microcarriers for cell cultures used in regenerative medicine. The product is scheduled for launch in January 2024 in Japan and overseas, beginning in the US..
• In June 2023, Teijin Frontier introduced new nonwoven microcarriers that enable speedy, large-scale, high-quality cell culture. The new nonwoven microcarriers combine Teijin Frontier’s proprietary fiber process and nonwoven design technology, and fiber-related biomedical expertise by the Faculty of Engineering, University of Fukui, Japan. 
• In October 2023, Semarion, unveiled the Early Adopter Programme for its SemaCyte Microcarrier Platform. SemaCytes developed by Semarion are cell carrier materials created using microchip fabrication technologies, nanomagnetism, and smart materials. These assaying microcarriers are flat and function as ultraminiaturized, magnetically steerable wells that carry small colonies of adherent cells into suspension to improve cell-based experiments.
• In January 2022, FUJIFILM Corporation announced its plan to acquire from Atara Biotherapeutics, Inc’s cell therapy manufacturing facility. The facility is readily expandable and flexible to produce clinical and commercial cell therapies, including allogeneic T-cell and CAR T immunotherapies.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com